Bicycle Therapeutics

Historical price data

Bicycle Therapeutics is a UK-based, NASDAQ-listed biotech pioneering a novel class of synthetic, constrained peptide therapeutics. Its core Bicycle® platform generates molecules designed to deliver the high specificity of biologics with the favorable pharmacokinetics of small molecules, enabling deep tissue penetration in solid tumors. The company has advanced multiple wholly-owned and partnered programs into clinical development, focusing on oncology targets like Nectin-4 and EphA2, while actively exploring partnerships to expand into other therapeutic areas. Its strategy is to build a leading solid tumor medicine portfolio, validated by clinical data and strategic collaborations.

Proprietary Bicycle® platform for generating fully synthetic, constrained peptides that combine the specificity of antibodies with the tissue-penetrating properties of small molecules, enabling targeted delivery in solid tumors and conditional immune activation.